Glenmark Life Sciences Limited
NSE:GLS.NS
1096.1 (INR) • At close November 8, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) INR.
| 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operationele Activiteiten: | |||||||||||||||||
| Nettowinst
| 1,114.83 | 979.37 | 1,187.65 | 1,187.37 | 1,354.5 | 1,463.57 | 1,049.93 | 1,068.78 | 1,087.33 | 988.97 | 1,037.13 | 1,152.01 | 1,009.13 | 1,046.84 | 933.61 | 724.7 | 810.66 |
| Afschrijvingen & Amortisatie
| 0 | 0 | 131.77 | 131.29 | 126.12 | 115.17 | 107.63 | 99.35 | 0 | 0 | 0 | 0 | 0 | 78.81 | 78.01 | 0 | 0 |
| Uitgestelde Inkomstenbelasting
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Aandelen Gebaseerde Vergoedingen
| 0 | 43.75 | 0 | 0 | 0 | 31.85 | 0 | 0 | 0 | 34.98 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verandering in Werkkapitaal
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 835.17 | -260.5 | 0 | 0 |
| Vorderingen
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,013.39 | -358.42 | 0 | 0 |
| Voorraden
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -52.95 | 56.38 | 0 | 0 |
| Crediteuren
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overig Werkkapitaal
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -125.27 | 41.54 | 0 | 0 |
| Overige Niet-Contante Posten
| -1,114.83 | -979.37 | -1,187.65 | -1,187.37 | -1,354.5 | -1,495.42 | -1,049.93 | -1,068.78 | -1,087.33 | -1,023.95 | -1,037.13 | -1,152.01 | -1,009.13 | -183.37 | -110.92 | -724.7 | -810.66 |
| Kasstroom uit Operationele Activiteiten
| 0 | 0 | 263.54 | 262.58 | 252.24 | 31.85 | 215.26 | 198.7 | 0 | 34.98 | 0 | 0 | 0 | 1,777.45 | 640.2 | 0 | 0 |
| Investeringsactiviteiten: | |||||||||||||||||
| Investeringen in Materiële Vaste Activa
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -243.82 | -136.4 | 0 | 0 |
| Netto Overnames
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Aankoop van Beleggingen
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop/verval van Beleggingen
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overige Investeringsactiviteiten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -20.73 | 9.5 | 0 | 0 |
| Kasstroom uit Investeringsactiviteiten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -264.55 | -126.9 | 0 | 0 |
| Financieringsactiviteiten: | |||||||||||||||||
| Schuldaflossingen
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Uitgifte van Gewone Aandelen
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Terugkoop van Gewone Aandelen
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Uitgekeerde Dividenden
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overige Financieringsactiviteiten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -467.82 | -568.78 | 0 | 0 |
| Kasstroom uit Financieringsactiviteiten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -467.82 | -568.78 | 0 | 0 |
| Overige Informatie: | |||||||||||||||||
| Effect van Wisselkoersveranderingen op Kas
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 166.36 | 0 | 0 |
| Netto Kasstroomverandering
| 0 | 0 | 263.54 | 262.58 | 252.24 | 31.85 | 215.26 | 198.7 | 0 | 34.98 | 0 | 0 | 0 | 1,045.08 | 110.88 | 0 | 0 |
| Kaspositie aan het Einde van de Periode
| 0 | 0 | 4,694.26 | 4,430.72 | 3,346.21 | 3,093.97 | 3,860.87 | 3,645.61 | 0 | 34.98 | 0 | 0 | 1,155.96 | 1,155.96 | 110.88 | 0 | 0 |